ReviewJournal of medicinal chemistry2020
The Essential Medicinal Chemistry of Cannabidiol (CBD).
Review in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed.
- (+)-Trans-Cannabidiol Is an Agonist at Human CBPharmacology research & perspectives · 2026Article
- Acrylamide-Induced Neurotoxicity Is Mitigated by Curcumin and Its Nano Lipid Carrier Formulation in Albino Rats.Environmental toxicology · 2026Article
- Cytochrome P450-Catalyzed Hydroxylation of Δ8-Tetrahydrocannabinol and Implications for Pharmacogenetics.Pharmaceutics · 2026Article
- Whole-Cell Transformation of Cannabidiol by Selected Filamentous Fungi into Novel Polar Derivatives.International journal of molecular sciences · 2026Article
- Solubility-improved and antitumor activity of (-)-cannabidiol conjugates.Journal of cannabis research · 2026Article
- Inhibitory effect of cannabidiol on infectious bronchitis virus in chickens in vitro and in vivo.Archives of microbiology · 2026Article
- Lipid Nanoparticles with Stiripentol and Cannabidiol Oil: From Rational Optimization to Preclinical Characterization.Pharmaceutics · 2026Article
- Cannabidiol: Pharmaceutical formulations and biomedical applications.Iranian journal of basic medical sciences · 2026Review
- Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.Clinical and translational science · 2026Article
- Unraveling Cannabidiol's Bidirectional Regulation of Melatonin Pharmacokinetics via PEPT1/CYP1A2: Mechanistic Insights and Quantitative Projections.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- NAD(P)Archives of toxicology · 2025Article
- Metabolism of Cannabidiol in Respiratory-Associated Cells and HepG2-Derived Cells and Molecular Docking of Cannabidiol and Its Metabolites with CYP Enzymes and Cannabinoid Receptors.International journal of molecular sciences · 2025Article
- Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.Biomolecules · 2025Review
- Cannabis Derivatives as Ingredients of Functional Foods to Combat the COVID-19 Pandemic.Foods (Basel, Switzerland) · 2025Review
- Exploring the Potential of Phytocannabinoids Against Multidrug-Resistant Bacteria.Plants (Basel, Switzerland) · 2025Article
- Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson's and Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Beyond the hype: a comprehensive exploration of CBD's biological impacts and mechanisms of action.Journal of cannabis research · 2025Review
- Optimising Cannabidiol Delivery: Improving Water Solubility and Permeability Through Phospholipid Complexation.International journal of molecular sciences · 2025Article
- Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties.Molecules (Basel, Switzerland) · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This Perspective of the published essential medicinal chemistry of cannabidiol (CBD) provides evidence that the popularization of CBD-fortified or CBD-labeled health products and CBD-associated health claims lacks a rigorous scientific foundation. CBD's reputation as a cure-all puts it in the same class as other "natural" panaceas, where valid ethnobotanicals are reduced to single, purportedly active ingredients. Such reductionist approaches oversimplify useful, chemically complex mixtures in an attempt to rationalize the commercial utility of natural compounds and exploit the "natural" label. Literature evidence associates CBD with certain semiubiquitous, broadly screened, primarily plant-based substances of undocumented purity that interfere with bioassays and have a low likelihood of becoming therapeutic agents. Widespread health challenges and pandemic crises such as SARS-CoV-2 create circumstances under which scientists must be particularly vigilant about healing claims that lack solid foundational data. Herein, we offer a critical review of the published medicinal chemistry properties of CBD, as well as precise definitions of CBD-containing substances and products, distilled to reveal the essential factors that impact its development as a therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.